FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY

Project Information

MYCureX

Grant agreement ID: 101144681

DOI

10.3030/101144681

Project closed

EC signature date 8 February 2024

Start date 1 July 2023

End date 31 December 2025

Funded under

• The European Innovation Council (EIC)

Total cost

€ 3 563 578,25

EU contribution

€ 2 494 504,00

Coordinated by

PEPTOMYC SL
Spain

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.

Author(s): Fabio Giuntini; Íñigo González-Larreategui; Andrea Herencia-Ropero; Silvia Casacuberta-Serra; Mariano F. Zacarías-Fluck; Magdalena Arnal; Flaminia Pedretti; Sandra Martínez-Martín; Hugo Thabusso
Published in: Cell Reports, 2025, ISSN 2211-1247
Publisher: Cell Press
DOI: 10.1016/j.celrep.2025.116604

Intellectual Property Rights

Other (2)

Compound for the treatment of autoimmune diseases

Application/Publication number: EP24382257.4 EP24382257.4
Date: 2024-03-11
Applicant(s): PEPTOMYC SL

Compound for the treatment of autoimmune diseases

Application/Publication number: EP24382257.4 EP24382257.4
Date: 2024-03-11
Applicant(s): PEPTOMYC SL